Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech Firms Urge NIH To Share Stimulus Funds With Small Businesses

This article was originally published in The Gray Sheet

Executive Summary

A U.S. senator from Maryland is calling for the National Institutes of Health to set aside a portion of federal stimulus funds for use in the Small Business Innovative Research (SBIR) grant program

You may also be interested in...



Revamp Of Small Business Grant Program Is Back On The Table

Device start-ups are optimistic that legislation allowing more venture capital-backed firms to participate in a federal small business grants program will pass in this Congress

House Passes SBIR Reauthorization, Loosens Venture Capital Restrictions

A bill reauthorizing the Small Business Innovation Research (SBIR) program passed the House April 23. It would allow larger federal research and development grants to small companies and give the firms more flexibility in seeking funds from both federal agencies and venture capitalists

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel